Aytu BioPharma, Inc.

What they do

Aytu BioPharma commercializes prescription pharmaceuticals in the U.S., operating as a single segment after divesting its Consumer Health business. Its portfolio includes the ADHD products Adzenys XR-ODT and Cotempla XR-ODT, and pediatric products Karbinal ER and Poly-Vi-Flor/Tri-Vi-Flor. The company's primary focus is the launch of EXXUA (gepirone), a first-in-class 5HT1a receptor agonist approved for MDD, which was made commercially available in mid-December 2025.

Revenue drivers

• ADHD Portfolio — Adzenys XR-ODT and Cotempla XR-ODT generate the majority of revenue; Q3 FY2026 net revenue was $9.1 million, down from $15.4 million a year ago due to sales force reallocation and generic competition.
• EXXUA (gepirone) — Newly launched in the U.S. for MDD; contributed $2.4 million in net revenue in Q3 FY2026 (partial quarter of full sales force support), with >1,300 prescriptions written by >450 prescribers.
• Pediatric Portfolio — Legacy products including Karbinal ER and fluoride supplements; Q3 FY2026 net revenue was $0.9 million, down from $3.1 million due to payor changes and higher returns.

Recent performance

In Q3 FY2026 (quarter ended March 31, 2026), Aytu reported total net revenue of $12.4 million, down from $18.5 million in Q3 FY2025, with declines across the ADHD and Pediatric portfolios. Net loss was $5.6 million, including a $1.3 million loss on derivative warrant liabilities, compared to net income of $4.0 million in the prior-year quarter. Adjusted EBITDA was negative $2.8 million, reflecting launch investments. Cash and equivalents were $26.7 million at March 31, 2026. Full-year net losses narrowed from $15.8M in FY2024 to $13.6M in FY2025, with FY2025 revenue of $66.4M.

Strategy

Management's stated strategy is to build a leading CNS-focused pharmaceutical company through in-licensing, acquisition, and commercialization of novel prescription therapeutics. The company has indefinitely suspended clinical development programs and divested its Consumer Health business to focus on the EXXUA launch and its existing commercial products. It plans to leverage its commercial team to drive EXXUA adoption while maintaining the ADHD and Pediatric portfolios as a profitable foundation. The company aims to achieve positive operating cash flow.

Risks

• Ongoing losses — Aytu has incurred losses in every year since inception, with a $13.6 million net loss in FY2025, and cannot assure profitability.
• Generic competition — Generic competition for Adzenys XR-ODT has already reduced ADHD segment revenue, and further erosion could occur.
• EXXUA launch uncertainty — The success of EXXUA depends on market acceptance, reimbursement, and competitive dynamics in the $22 billion MDD market; early results may not sustain.
• Capital and liquidity — With $26.7 million in cash and recurring losses, the company may require additional funding to support the EXXUA launch and operations.

Outlook

Management expects EXXUA to be a major growth catalyst and anticipates continued compounding script growth, citing early refill activity and channel partner readiness. They plan to continue disciplined commercial execution while preserving the profitability of the ADHD and Pediatric portfolios. No specific revenue or profitability guidance was provided, but the company emphasized achieving positive operating cash flows as a goal.